To Optimize Treatment for your Breast Cancer Patients
Personalized medicine helps guide ER+, HER2-, N0 and N+, pre or post-menopausal breast cancer treatment decisions

The ONLY test that answers the following three important clinical questions...

Can chemotherapy be avoided? (Risk at 10 years¹)

What is the absolute benefit from chemotherapy? (Chemotherapy benefit²)

Can the extension of endocrine therapy be avoided? (Risk between 5 and 15 years³)

... to optimize treatment for your breast cancer patients

EndoPredict is designed for women with ER+, HER2- primary breast cancer (node-negative or node positive (micrometastases, 1-3 nodes), pre- or postmenopausal)
One Test – Three Clinical Answers

EndoPredict is a gene expression assay for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer who are lymph node negative or positive (N0, N+). The second generation test combines a molecular score with tumor size and nodal status to provide more prognostic power than first generation tests.

In the result report the individual risk, either low or high, is clearly indicated for each patient. In addition the risk of early and late distant recurrence with 5 years of adjuvant endocrine therapy alone and the estimated absolute benefit of chemotherapy are determined.

EndoPredict provides highly important and clear information for different stages of treatment planning.

**Initial treatment planning:**
10-year risk of recurrence for patients with node negative or node positive disease¹ and estimated absolute chemotherapy benefit at 10 years based on modern treatment regimens.²

**Long-term treatment planning:**
Breast cancer recurrence risk out to 15 years.³

Patients at low risk of distant recurrence are usually treated initially without chemotherapy. Under endocrine therapy alone, more than 95% of EndoPredict low-risk patients do not experience a distant recurrence, even more than 10 years after diagnosis.¹

Compared to risk stratification using clinical parameters or other gene expression tests, EndoPredict identifies the largest group of women with breast cancer at low risk (<10% chance of distant recurrence in 10 years) who might safely avoid chemotherapy.⁴,⁵,⁶

For even more treatment confidence, EndoPredict predicts the individual absolute chemotherapy benefit based on modern treatment regimens.³

In addition EndoPredict can support long-term treatment planning. Some patients can benefit from prolonged endocrine therapy up to ten years, but other patients can avoid this additional treatment and be safely treated with only 5 years of endocrine therapy.

EndoPredict is the only test that provides your patient’s individual risk of breast cancer late distant recurrence within years 5-15³ to help in deciding whether your patient can avoid extended endocrine therapy.

EndoPredict is the only prognostic test that can help in deciding whether your patient can safely avoid chemotherapy, how beneficial chemotherapy would be, and whether your patient can avoid extended endocrine therapy.
Measures 8 Genes related to Early and Late Recurrence

**Endopredict** was developed using consistent criteria for patients during training and independent validation studies on 10 year outcome data. ER+/HER2- breast cancer, both N0 and N+.

The **Endopredict** algorithm was generated in a large training set of 964 ER+/HER2- breast cancer samples.1

**Consistent study cohorts for training and validation**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Assigned biological processes</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBE2C</td>
<td>Protein degradation, cell division</td>
</tr>
<tr>
<td>BIRC5</td>
<td>Anti-apoptosis, cell division, cytokinesis, chromosome localization</td>
</tr>
<tr>
<td>DHCR7</td>
<td>Cholesterol biosynthesis</td>
</tr>
<tr>
<td>STC2</td>
<td>Cell-to-cell communication</td>
</tr>
<tr>
<td>AZGP1</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td>IL6ST</td>
<td>Various signal transduction pathways, cell proliferation, T cell proliferation</td>
</tr>
<tr>
<td>RBBP8</td>
<td>DNA repair</td>
</tr>
<tr>
<td>MGP</td>
<td>Transcriptional regulation</td>
</tr>
</tbody>
</table>

**Proliferation and hormone receptor related genes for early and late recurrence**

EndoPredict measures the activity of eight genes relevant to the course of disease (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, STC2). Inclusion of proliferation and hormone receptor related genes contributes to accurate assessment of early and late recurrence risk.1,7

These eight genes are compared against three normalization genes (OAZ1, CALM2, RPL37A) and one control gene (HBB). Based on the activity of the genes, the **12-Gene Molecular Score** is calculated using a mathematical algorithm and reported on a scale of 0 to 15.
The final EndoPredict result, the **EPclin Risk Score**, is calculated combining the 12-Gene Molecular Score with clinical pathological prognostic factors (tumor size and lymph node status) as assessed by the pathologist. This makes EndoPredict a second generation gene expression test and a more powerful predictor of prognosis.

The EPclin Risk Score is reported on a scale of 1 to 6. The value of 3.32867 is associated with 10% risk of breast cancer recurrence within 10 years. Values below 3.32867 are associated with low risk and values above or equal to 3.32867 with high risk.

**EndoPredict** provides a clear classification into **high risk and a low risk**

The EPclin Risk Score alone is a more powerful predictor of the prognosis than combinations of all classical prognostic factors. ¹

As a second generation gene expression test, EndoPredict is a more powerful predictor of prognosis than first generation assays. Prognostic power providing results you can trust.

**Second generation gene expression test** for more prognostic power

---

¹ Prognostic power according to the c-index in comparison to prognostic factors

---

**PROGNOSTIC POWER**

<table>
<thead>
<tr>
<th>EndoPredict</th>
<th>Molecular Score</th>
<th>Tumor Stage</th>
<th>Nodal Status</th>
</tr>
</thead>
</table>

* Oncotype DX, MammaPrint

---

**Prognostic power of gene expression assays**

---
The EndoPredict Result Report documents the molecular data and the established prognostic factors of tumor size and lymph node status.

Using a mathematical algorithm, the 12-gene molecular score is combined with the clinical data. This results in the patient’s individual **EPclin Risk Score** and subsequent classification as “low risk” or “high risk”.

An overview of the three clinical answers given by Endopredict is organized by treatment planning stage.

**Initial treatment planning**
1. Risk at 10 years - Can chemotherapy be avoided?
2. Chemotherapy benefit - What is the absolute benefit from chemotherapy?

**Long-term treatment planning**
3. Risk between 5 and 15 years - Can the extension of endocrine therapy be avoided?

Information is summarized by treatment planning stage.
Detailed Information on Three Clinical Questions

Can chemotherapy be avoided?

Each patient’s report will show a graphic curve illustrating her risk of recurrence within years 0-10 after diagnosis.

This information helps you to identify your patients with a low risk of recurrence who might safely avoid chemotherapy.

What is the benefit from chemotherapy?

The second graph in the report illustrates the absolute chemotherapy benefit based on whether the patient receives endocrine therapy alone or endocrine plus chemotherapy.

This helps your patient to make a confident chemotherapy treatment decision.

Can the extension of endocrine therapy be avoided?

The third graph on the report illustrates your patient’s risk of recurrence within years 5-15 after diagnosis.*

This information guides treatment decisions regarding endocrine therapy beyond 5 years.

*5-15 year risk is based on treatment with 5 years of ET only – no chemo. The result assumes the patient has not recurred by 5 years.
Independently Validated for Robust Prognostic Results

EndoPredict was developed using consistent criteria for patients during training and independent validation studies - ER+, HER2− patients, both node-negative (N0) and node-positive (N+). These "clean" cohorts are one reason for the test’s stronger performance compared to tests that included HER2+ patients in their training cohorts. The score and the cutoff value is consistent in all studies and has never changed.

The patients in the ABCSG6, ABCSG8 and TransATAC studies were treated with endocrine therapy alone. The prognostic value of EndoPredict under chemotherapy was demonstrated by the GEICAM/9906 study. All patients received only 5 years of hormone therapy.

Consistently identifies a large low risk group with a recurrence risk of less than 10%

Patients in training and validation studies

- Breast cancer subtype ER+, HER2-
- Nodal status N0 or N+
- Adjuvant treatment 5 years of endocrine therapy (not extended)

Validated in four prospective-retrospective studies \(^1, 2, 3, 4, 5, 8\) providing level 1 evidence

---

### EndoPredict training and validation studies

<table>
<thead>
<tr>
<th>Trial</th>
<th># of patients</th>
<th>Breast cancer sub-type</th>
<th>Nodal Status</th>
<th>Treatment</th>
<th>10-year distant metastasis rate in low-risk group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multicenter</td>
<td>964</td>
<td>ER+/HER2-</td>
<td>N0, N+</td>
<td>E</td>
<td>7%</td>
</tr>
<tr>
<td>Validation I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABCSG-6(^1)</td>
<td>378</td>
<td>ER+/HER2-</td>
<td>N0, N+</td>
<td>E</td>
<td>4%</td>
</tr>
<tr>
<td>Validation II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABCSG-8(^1)</td>
<td>1,324</td>
<td>ER+/HER2-</td>
<td>N0, N+</td>
<td>E</td>
<td>4%</td>
</tr>
<tr>
<td>Validation III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEICAM/9906(^8)</td>
<td>555</td>
<td>ER+/HER2-</td>
<td>N+</td>
<td>E + CT</td>
<td>0%</td>
</tr>
<tr>
<td>Validation IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TransATAC(^5)</td>
<td>928</td>
<td>ER+/HER2-</td>
<td>N0, N+</td>
<td>E</td>
<td>5.8%</td>
</tr>
</tbody>
</table>

EndoPredict training and validation studies

Analysis of ER+, HER2−, N+ and N0 patients from ABCSG-6, ABCSG-8 and TransATAC\(^1, 5\)
Identifies Clear Risk Groups in Different Subgroups

EndoPredict supplies additional prognostic information to supplement common prognostic factors such as nodal status, tumor grade or Ki67. This has been demonstrated in four validation studies.

EndoPredict identifies a large percentage of low risk patients (average of 6% recurrence) 1, 3, 5, 6
- More than 70% of N0 patients
- Up to 30% of N+ patients

Risk assessment independent of nodal status

EndoPredict identifies high and low risk patients independent from tumor grade.2
- 22% high risk in grade 1 patients
- 60% low risk in grade 2 patients
- 19% low risk in grade 3 patients

Risk assessment independent of grading
Significantly increases the low risk group

Patients at low risk of recurrence do not always require chemotherapy. Based on previous guidelines that did not yet include gene expression tests, only a few patients could be clearly identified as low risk. Depending on the guideline used, only 6%-19% of patients were classified as low risk in the ABCSG-6&8 study cohorts.

With the additional information supplied by EndoPredict, 63% of patients were categorized as low risk. This means that – based on the EndoPredict test result – many more patients might optimally be treated without chemotherapy.

More patients can safely forgo chemotherapy

Kaplan-Meier curve for recurrence free survival from (A) National Comprehensive Cancer Center Network (NCCN) guideline (2007), (B) German S3 Guidelines (2008), (C) St. Gallen Consensus (2011) and (D) EPclin risk groups.
A patient categorized as intermediate risk from the guidelines has an unclear treatment pathway. With EndoPredict, this intermediate risk group can be divided into a low-risk and a high-risk group.

The much larger EndoPredict low risk group shows a comparable risk of distant metastasis to the group defined as low risk by the guideline.⁴

The clear risk assessment for a period of more than ten years provides greater long-term therapeutic confidence for patients and physicians.

Current guidelines therefore recommend using gene expression analyses in unclear cases (NCCN, ASCO, AGO, ESMO, St. Gallen, EGTM and AJCC).
Shows Absolute and Relative Benefit of Chemotherapy

EndoPredict predicts chemotherapy benefit in women with ER-positive, HER2-negative disease. Chemobenefit was validated in a large study with over 3,700 patients with ER+, HER2- breast cancer. 2,630 patients were treated with 5 years of endocrine therapy alone and 1,116 patients were treated with endocrine plus chemotherapy with modern (taxane and/or anthracycline-containing) treatment regimens.

### EPclin Risk Score Table

<table>
<thead>
<tr>
<th>EPclin Risk Score</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>3.3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 year risk for DRFI</td>
<td>1.0%</td>
<td>2.8%</td>
<td>7.6%</td>
<td>10.2%</td>
<td>19.8%</td>
<td>46.1%</td>
<td>82.2%</td>
</tr>
<tr>
<td>(0.6-1.4)</td>
<td>(2.1-3.5)</td>
<td>(6.4-8.8)</td>
<td>(8.8-11.6)</td>
<td>(17.6-22.0)</td>
<td>(40.2-51.4)</td>
<td>(72.1-88.6)</td>
<td></td>
</tr>
<tr>
<td>10.2%</td>
<td>25.8%</td>
<td>49.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(4.1-7.2)</td>
<td>(5.4-8.9)</td>
<td>(10.1-14.6)</td>
<td>(22.0-29.5)</td>
<td>(40.5-56.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Absolute benefit

-0.1% 0.3% 1.9% 3.0% 7.4% 20.3% 33.0%

### Relative benefit

-0.1 0.11 0.25 0.29 0.37 0.44 0.40

In patients with low EPclin Risk Scores, no differences in 10 year risks were observed between endocrine treatment alone and endocrine treatment plus chemotherapy.

Patients with a low risk EndoPredict result did not benefit from the addition of chemotherapy.

Patients with a high risk EndoPredict result had a stronger benefit from chemotherapy. This benefit was more than proportional.

**Personalized absolute chemotherapy benefit for confident treatment decisions**

For an EPclin score of 5.0, women receiving ET alone had a 10-year DRFI risk of 46.1% compared to 25.8% for women who received ET+C.
After 5 years of endocrine therapy, breast cancer recurrences in ER+ tumors continue to occur steadily up to 20 years after diagnosis. Of those patients with ER+ breast cancer who experience recurrent disease, more than 50% occur after 5 years.\(^9\),\(^10\)

Therefore assessment of risk out to 10 or 15 years is important to identify the subgroup of patients who may benefit from extended endocrine therapy beyond 5 years.

EndoPredict is the only prognostic test that successfully predicts risk of early (0-10 years) and late (5-15 years) recurrence for patients with node-negative and node-positive disease.\(^3\)

Late recurrence risk was validated in over 1,300 ER+, HER2- patients. Analyses were performed for the overall cohort, by nodal status, and for patients who were distant recurrence-free at year 5 (late recurrence).

EndoPredict low-risk patients had a consistent low risk of recurrence in years 0-10 and 5-15. The results for the late distant recurrence period (5-15 years) indicate that EPclin Risk Score is informative for selecting patients who may safely forgo extended endocrine therapy.

### Guides treatment decisions regarding extended endocrine therapy

- **Risk of breast cancer death after initial diagnosis:**\(^9\)
- **Kaplan–Meier curves of estimated DRFR:**\(^1\)

---

**Provides Recurrence Risk out to 15 years**

---

**EPclin Low**

- 0-10 Year DRFR: 95.5% (94.1%, 97.0%)
- 5-15 Year DRFR: 95.7% (93.4%, 98.1%)

**EPclin High**

- 0-10 Year DRFR: 80.3% (76.9%, 83.9%)
- 5-15 Year DRFR: 84.1% (78.9%, 89.6%)

**Numbers at risk by EPclin risk group**

<table>
<thead>
<tr>
<th>Time in Years</th>
<th>EPclin Low</th>
<th>EPclin High</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-10 years</td>
<td>1067</td>
<td>1042</td>
</tr>
<tr>
<td>5-15 years</td>
<td>897</td>
<td>769</td>
</tr>
</tbody>
</table>

**HR 4.77 (3.37, 6.67), p<0.0001**

**HR 4.52 (2.65, 7.72), p<0.0001**

---

**Numbers at risk by EPclin risk group**

<table>
<thead>
<tr>
<th>Time in Years</th>
<th>EPclin Low</th>
<th>EPclin High</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-10 years</td>
<td>1067</td>
<td>1042</td>
</tr>
<tr>
<td>5-15 years</td>
<td>897</td>
<td>769</td>
</tr>
</tbody>
</table>

---

**Distant Recurrence Free (%)**

- **0-15 years**
  - EPclin Low: 95.5% (94.1%, 97.0%)
  - EPclin High: 80.3% (76.9%, 83.9%)

- **5-15 years**
  - EPclin Low: 95.7% (93.4%, 98.1%)
  - EPclin High: 84.1% (78.9%, 89.6%)

**HR 4.77 (3.37, 6.67), p<0.0001**

**HR 4.52 (2.65, 7.72), p<0.0001**

---

**Kaplan–Meier curves of estimated DRFR:**\(^1\)
Fast and Reliable

EndoPredict is performed on FFPE tumor tissue from biopsy or surgical specimens from patients who have not received systemic endocrine therapy and/or chemotherapy.

Once the sample has been sent to the laboratory, results are usually available within 1 week.

Results within 1 week for fast therapy decisions

An EndoPredict assay takes less than 8 hours in the normal operation of a molecular pathology laboratory. Only a small section of the tumor block (10 μm) is required. The tumor content of the tissue sample must be at least 30%. The subsequent RNA extraction is followed by reverse transcription (transcription of RNA into the corresponding cDNA sequence) and quantitative PCR. The gene expression values of all the relevant genes are determined, and the 12-Gene Molecular Score is calculated.

Analysis and quality assurance remain in the hands of the local pathologists. EndoPredict consistently delivers the same quality of results, regardless of the pathological institute conducting the assay, as has been demonstrated in round-robin testing. Implementing this procedure at a new site requires 2 days of installation and qualification.

This process guarantees the consistent reliability of the EndoPredict result, regardless of the laboratory conducting the assay.
Proven in Practice

Decision impact studies conducted at different centers documented how EndoPredict results affect the treatment decision in clinical practice.\textsuperscript{14, 15, 16, 17, 18}

The treatment plan of each participating patient was discussed before and after release of the EndoPredict result. In the first three mentioned studies in 25.4%, 28.4% and 38% of cases, the treatment decision in favor of chemotherapy was reversed, and the patient was advised to receive endocrine therapy alone. In 12.3%, 7.5% and 5% of cases, chemotherapy was recommended to avoid undertreatment.

Changes in therapy aligned with test result.

<table>
<thead>
<tr>
<th>Country</th>
<th>Germany</th>
<th>France</th>
<th>Germany</th>
<th>UK</th>
<th>Mexico</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution</td>
<td>Charité Berlin</td>
<td>Centre Jean Perrin Clermont-Ferrand</td>
<td>Technical University Munich</td>
<td>University of Sussex Brighton</td>
<td>National Institute of Cancerology Monterrey</td>
</tr>
<tr>
<td>Publication/Conference</td>
<td>PlosOne 2013</td>
<td>SABCS 2016</td>
<td>PlosOne 2017</td>
<td>Psycho Oncology 2018</td>
<td>SABCS 2018</td>
</tr>
<tr>
<td>First author</td>
<td>Mueller et al.\textsuperscript{14}</td>
<td>Penault-Llorca et al.\textsuperscript{15}</td>
<td>Ettl et al.\textsuperscript{16}</td>
<td>Fallowfield et al.\textsuperscript{17}</td>
<td>Villarreal-Garza et al.\textsuperscript{18}</td>
</tr>
<tr>
<td># patients</td>
<td>167</td>
<td>201</td>
<td>395</td>
<td>149</td>
<td>91</td>
</tr>
<tr>
<td>EPclin low risk</td>
<td>46%</td>
<td>67%</td>
<td>63%</td>
<td>50%</td>
<td>46%</td>
</tr>
<tr>
<td>EPclin high risk</td>
<td>54%</td>
<td>33%</td>
<td>37%</td>
<td>50%</td>
<td>54%</td>
</tr>
<tr>
<td>N0</td>
<td>62%</td>
<td>91%</td>
<td>77%</td>
<td>67%</td>
<td>72%</td>
</tr>
<tr>
<td>N+</td>
<td>38%</td>
<td>9%</td>
<td>23%</td>
<td>33%</td>
<td>28%</td>
</tr>
<tr>
<td>Change of therapy recommendation</td>
<td>37.7%</td>
<td>35.8%</td>
<td>43.0%</td>
<td>36.9%</td>
<td>17.0%</td>
</tr>
<tr>
<td>Net change CT</td>
<td>-13.1%</td>
<td>-20.9%</td>
<td>-33.0%</td>
<td>+0.7%</td>
<td>-10.53%</td>
</tr>
</tbody>
</table>

Decision Impact Studies with EndoPredict
Low Risk Results you can Trust

Decisions on the use of adjuvant chemotherapy in ER+, HER2- primary breast cancer are guided by the risk of distant recurrence.

EndoPredict and Oncotype DX® are prognostic gene expression tests used for estimating distant recurrence risk. EndoPredict provides prognostic information from a molecular signature combined with tumor size and nodal status (EPclin Risk Score). Oncotype DX provides prognostic information from a molecular signature only (Recurrence Score RS).

In the TransATAC study the prognostic abilities of EPclin Risk Score and RS were compared directly. A total of 928 patients treated with 5 years endocrine therapy only were included. The primary endpoint was 10 year distant recurrence free survival. 5

The classification by EndoPredict aligns more closely with the patient outcomes

EndoPredict demonstrates superior prognostic performance independent from cutoff values

*The χ²-value is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the χ²-value, the better is the prognostic power of a test. The χ²-value reflects the prognostic power of the continuous score independent from cutoff values.

** RS non low = RS intermediate plus RS high.
Outperforms other Signatures

The TransATAC study also compared the performance of four commercially available prognostic signatures for breast cancer distant recurrence (DR) in years 0-10 and in years 5-10. A total of 774 patients treated with 5 years endocrine therapy only were included.  

***The C-index is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the C-Index, the better is the prognostic power of a test. The C-Index reflects the prognostic power of the continuous score independent from cutoff values.

EndoPredict identified most node negative patients as low risk

EndoPredict identified most node positive patients with "true" low risk

EndoPredict was the most prognostic signature indipendent from cutoff values

***The C-index is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the C-Index, the better is the prognostic power of a test. The C-Index reflects the prognostic power of the continuous score independent from cutoff values.
CE Marked as *in vitro* Diagnostic

EndoPredict meets the European regulatory requirements for safety, scientific validity, and clinical benefit. It can be used to improve the quality and safety of treatment of breast cancer patients in different disease stages.

- Validated in four clinical studies, including endocrine only and modern chemotherapy treatment
- Prospective-retrospective approach
- Level of evidence 1

- Identifies a large low-risk group with "true" low risk (<10%)
- Is a more powerful predictor than combinations of all classical prognostic factors
- Provides substantially more prognostic information than other gene expression tests
- Predicts early (0-10 years) and late recurrences (5-15 years)
- Provides personalized absolute chemotherapy benefit
- Prognostic in node positive and negative, pre and post menopausal patients

- Answers three important clinical questions
- Results available within one week for fast treatment decisions
- Guides clinical treatment and changes therapy decision in 30-40% of patients
- Increases the size of the low-risk group with very good prognosis
- Reduces chemotherapy associated costs with improvement of QALYs
- Recommended by international guidelines

- Meets the essential requirements of European Directive 98/79/EC (IVDD)
- Can be performed locally
- Reliable decentralized procedure
- Uses FFPE tissue (punch biopsy or surgical specimen)

References:
1, 5, 6, 8

References:
1, 2, 3, 4, 5, 6, 7, 8

References:
11, 12, 13, 26, 27, 28
References:

2. Sestak I. et al.: Prediction of Distant Recurrence by EndoPredict in Patients with Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Received Adjuvant Endocrine Therapy plus Chemotherapy (ET+C) or Endocrine Therapy Alone (ET). SABCS 2018
3. Filipits M, et al.: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years. SABCS 2018
18. Villarreal-Gfarca C. et al.: Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients. SABCS 2018
Our Expert Pathologist

Assoc.Prof. Mirette Saad

MBBS (HONS), MD (HONS), MAACB, FRCPA, PhD
Chemical Pathology, PhD Molecular Genetics

Phone: 03 9538 6777
State: Victoria
Email: mirette.saad@clinicallabs.com.au

HOW TO ORDER

• Download the request form
• Fill in the patients details and clinical history
• Tick "EndoPredict"
• Ensure the referring clinician details are complete
• If known, provide the specimen details
• If you would like a copy report to be sent, please provide the details of the other clinician
• Fill in payment details

EndoPredict resources and request forms are available at www.clinicallabs.com.au/endopredict

For further information, or to enquire about ordering EndoPredict please contact Australian Clinical Labs Molecular department on (03) 9538 2259.

1300 134 111 VIC NSW SA NT
1300 367 674 Western Australia
www.clinicallabs.com.au